New 2024 updates to prior authorizations and post service claim edits

Security Health Plan requires prior authorization (PA) and post service claim edits (PSCE) on medications to ensure coverage and payment for those services. Several requirements have been added for 2024 as we work to make sure all care, services and treatments are medically necessary. These drugs will be reviewed for medical necessity by Magellan.

Magellan will implement additional PA's and PSCE's July 1, 2024, for the following drugs given in the office based and outpatient settings:

- Amtagvi® (lifileucel)
- Jubbonti® (denosumab)
- Wyost® (denosumab-bbdz)
- Tyenne® (tocilizumab-aazg)
- Lenmeldy® (atidarsagene autotemcel)
- Tevimbra® (tislelizumab)
- Wezlana® (ustekinumab-auub)
- Winrevair® (sotatercept-csrk)
- Vectibix® (panitumumab)

This is only the list of new prior authorizations and post service claim edits required of members and providers to ensure payment for services. You can review the full list of all medications that will require a prior authorization and/or post service claim edit on our website https://www.securityhealth.org/providers/medical-pharmacy. If you have any questions, please contact Security Health Plan Provider Relations at 1-800-548-1224.